DuPont submits MAA for Definity
In its continued effort to bring ultrasound contrast agent Definity to market, DuPont Pharmaceuticals has filed a marketing authorization application (MAA) for the agent with the European Medicines Evaluation Agency (EMEA). The application is based on
In its continued effort to bring ultrasound contrast agent Definity to market, DuPont Pharmaceuticals has filed a marketing authorization application (MAA) for the agent with the European Medicines Evaluation Agency (EMEA). The application is based on seven multicenter phase III clinical trials that included 610 patients at 52 U.S. medical centers and covers the use of Definity for contrast-enhanced ultrasound imaging of the heart and abdomen.
EMEAs review arm, the Committee for Proprietary Medicinal Products (CPMP), will examine the North Billerica, MA, companys application. If cleared by the CPMP, DuPont will be able to sell Definity in all of the European Union countries. DuPont has also filed a new drug submission (NDS) for Definity with the Health Protection Branch of Health Canada, and, in 1998, filed an NDA with the Food and Drug Administration (SCAN 12/16/98).
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.
